US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Mannkind Corp. Will Wait until Mid-July for FDA Review and FuelCell Energy Awarded $3M by U.S. Department of Energy

MannKind Corp. (NASDAQ: MNKD) reported recently that the U.S. Food and Drug Administration plans to take until mid-July to review its inhaled diabetes treatment. “We view an approval [of Afrezza] as the most likely outcome, given the overwhelmingly positive vote, but continue to see some risk in the decision,” Cowen & Co. analyst Simos Simeonidis said in a note to clients, adding that it appears the FDA sees the drug as a “real need” for patients who can’t or shouldn’t use injectable insulin. MannKind Corporation, a biopharmaceutical company, focuses on the discovery, development, and

MannKind Soars after FDA Advisers Back the Company’s Diabetes Treatment Afrezza and Macys Announces New President

Macy's, Inc. (NYSE: M) – shares hit a new all-time high of $60.88 during intra-day trading on Tuesday, a day after the company announced that it has named its former chief merchandising officer, Jeffrey Gennette as the company’s new president. Gennett will take over immediately and has already been serving the company in his former role since 2009. In his new role, he will supervise the company’s marketing and website related operations, apart from being in charge of Macy’s day-to-day merchandising activities. Macy's, Inc., together with its subsidiaries, operates stores and Internet

Mannkind Corp’s Afrezza Diabetes Device Raises Concerns and Idera Pharmaceuticals Announces Positive Phase 2 Trial Results

MannKind Corp. (NASDAQ: MNKD) shares dipped on Friday after a report from FDA staff raised some questions about the company’s diabetes device Afrezza. An FDA committee said it was concerned about certain pharmacology issues that could impact Afrezza’s safety and effectiveness. Concerns included the drug’s potential risks related to bronchospasms and pulmonary function decline in patients with underlying lung disease. The committee also said that available data from studies do not “conclusively support” use in patients with underlying lung disease. The committee issued their report before a

There are no items matching the current filter
There are no more items matching the current filter
Back to top